Advances in Therapy

, Volume 27, Issue 9, pp 623–633

Warfarin therapy in patients with venous thromboembolism: Patterns of use and predictors of clinical outcomes

  • Steven B. Deitelzweig
  • Jay Lin
  • Charles Kreilick
  • Mohamed Hussein
  • David Battleman
Original Research



Few studies have investigated current practices in the USA relating to warfarin use and monitoring, or the effects of warfarin discontinuation on risk of venous thromboembolism (VTE) and bleeding complications. This study investigated the effect of warfarin discontinuation on rates of VTE recurrence in a real-world setting.


Integrated Healthcare Information Services database records from January 2003 to September 2007 from patients aged at least 18 years, hospitalized for VTE, and with at least two prescriptions or 60 days of warfarin treatment were reviewed, with warfarin discontinuation and international normalized ratio (INR) data collated.


A total of 1027 of 8380 (12.3%) patients discontinued warfarin within 3 months. Overall, 1656 (19.8%) patients had no INR monitoring, with 38.1% of INR values being inside the therapeutic range (INR 2–3). Recurrent VTE was observed in 915 (10.9%) patients. Significant predictors of recurrent VTE (at any time) included discontinuation of warfarin within 3 months, time from index VTE to warfarin initiation, previous VTE-related hospitalization, and duration of index hospitalization.


This study found that in a real-world population, less than 50% of warfarin patients achieved INR values within the therapeutic range. Warfarin discontinuation within 3 months was associated with a higher rate of recurrent VTE.


anticoagulation prophylaxis venous thromboembolism warfarin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    White RH. The epidemiology 1. of venous thromboembolism. Circulation. 2003;107(suppl. 1): I4–I8.PubMedGoogle Scholar
  2. 2.
    Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med. 2004;164:963–968.CrossRefPubMedGoogle Scholar
  3. 3.
    Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117:19–25.CrossRefPubMedGoogle Scholar
  4. 4.
    Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160:769–774.CrossRefPubMedGoogle Scholar
  5. 5.
    Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761–768.CrossRefPubMedGoogle Scholar
  6. 6.
    Mohr DN, Silverstein MD, Heit JA, Petterson TM, O’Fallon WM, Melton LJ. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. Mayo Clin Proc. 2000;75:1249–1256.CrossRefPubMedGoogle Scholar
  7. 7.
    White RH, Zhou H, Kim J, Romano PS. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med. 2000;160:2033–2041.CrossRefPubMedGoogle Scholar
  8. 8.
    Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901–907.CrossRefPubMedGoogle Scholar
  9. 9.
    Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl.):454S–545S.CrossRefPubMedGoogle Scholar
  10. 10.
    Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med. 1999;159:46–48.CrossRefPubMedGoogle Scholar
  11. 11.
    Kimmel SE, Chen Z, Price M, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) study. Arch Intern Med. 2007;167:229–235.CrossRefPubMedGoogle Scholar
  12. 12.
    Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl.):160S–198S.CrossRefPubMedGoogle Scholar
  13. 13.
    US Department of Health & Human Services. Protection of Human Research Subjects. Available at: Accessed February 23, 2010.
  14. 14.
    Prins MH, Hutten BA, Koopman MM, Büller HR. Long-term treatment of venous thromboembolic disease. Thromb Haemost. 1999;82:892–898.PubMedGoogle Scholar
  15. 15.
    Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631–639.CrossRefPubMedGoogle Scholar
  16. 16.
    Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307:1676–1681.CrossRefPubMedGoogle Scholar
  17. 17.
    Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA. 2005;294:706–715.CrossRefPubMedGoogle Scholar
  18. 18.
    Schwarz M. Home monitoring of INR using point-of-care testing is a viable option for patient involvement (April 28, 2010). Available at: Accessed June 23, 2010.

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  • Steven B. Deitelzweig
    • 1
  • Jay Lin
    • 2
  • Charles Kreilick
    • 3
  • Mohamed Hussein
    • 4
  • David Battleman
    • 4
  1. 1.Ochsner Clinic FoundationNew OrleansUSA
  3. 3.Pro Unlimited Inc.Boca RatonUSA
  4. 4.IMS HealthFalls ChurchUSA

Personalised recommendations